STAT5 in Cancer and Immunity

Murphy, J.J. and Rani, A. 2016. STAT5 in Cancer and Immunity. Journal of Interferon & Cytokine Research. 36 (4), pp. 226-237. doi:10.1089/jir.2015.0054

TitleSTAT5 in Cancer and Immunity
AuthorsMurphy, J.J. and Rani, A.
Abstract

Signal transducers and activators of transcription 5 (STAT5a and STAT5b) are highly homologous proteins that are encoded by 2 separate genes and are activated by Janus-activated kinases (JAK) downstream of cytokine receptors. STAT5 proteins are activated by a wide variety of hematopoietic and nonhematopoietic cytokines and growth factors, all of which use the JAK-STAT signalling pathway as their main mode of signal transduction. STAT5 proteins critically regulate vital cellular functions such as proliferation, differentiation, and survival. The physiological importance of STAT5 proteins is underscored by the plethora of primary human tumors that have aberrant constitutive activation of these proteins, which significantly contributes to tumor cell survival and malignant progression of disease. STAT5 plays an important role in the maintenance of normal immune function and homeostasis, both of which are regulated by specific members of IL-2 family of cytokines, which share a common gamma chain (γc) in their receptor complex. STAT5 critically mediates the biological actions of members of the γc family of cytokines in the immune system. Essentially, STAT5 plays a critical role in the function and development of Tregs, and consistently activated STAT5 is associated with a suppression in antitumor immunity and an increase in proliferation, invasion, and survival of tumor cells. Thus, therapeutic targeting of STAT5 is promising in cancer.

KeywordsSTAT5; Cancer
JournalJournal of Interferon & Cytokine Research
Journal citation36 (4), pp. 226-237
ISSN1079-9907
Year2016
PublisherMary Ann Liebert
Accepted author manuscriptfinal version STAT5 review_revised_JICR_041115.docx
Digital Object Identifier (DOI)doi:10.1089/jir.2015.0054
Publication dates
Published05 Apr 2016
Published30 Dec 2015

Related outputs

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Rani, A., Stebbing, J., Giamas, G. and Murphy, J.J. 2019. Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy. Frontiers in endocrinology. 10, p. 245. doi:10.3389/fendo.2019.00245

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Sinha, U. 2017. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology . 57 (2), p. 194–210. doi:10.1002/jcph.794

HES1 in immunity and cancer
Rani, A., Greenlaw, R., Smith, R.A. and Galustian, C. 2016. HES1 in immunity and cancer. Cytokine & Growth Factor Reviews. 30, pp. 113-117. doi:10.1016/j.cytogfr.2016.03.010

Evidence for targeting of CD38 mRNA by the post-transcriptional regulator protein ZFP36L1
Murphy, J.J. 2015. Evidence for targeting of CD38 mRNA by the post-transcriptional regulator protein ZFP36L1. 4th European Congress of Immunology. Vienna 08 Sep 2015

The Notch target Hes1, is a STAT5 target gene with implications in cancer
Rani, A., Greenlaw, R., Galustian, C. and Murphy, J.J. 2015. The Notch target Hes1, is a STAT5 target gene with implications in cancer. 2015 Meeting of the ICIS in Bamberg, Germany, October 11th -14th. Bamberg, Germany Oct 2015 doi:10.1016/j.cyto.2015.08.214

Post-Transcriptional Regulation of BCL2 mRNA by the RNA-Binding Protein ZFP36L1 in Malignant B Cells
Zekavati, A., Nasir, A., Alcaraz, A., Aldrovandi, M., Marsh, P., Norton, J.D. and Murphy, J.J. 2014. Post-Transcriptional Regulation of BCL2 mRNA by the RNA-Binding Protein ZFP36L1 in Malignant B Cells. PLoS ONE. doi:10.1371/journal.pone.0102625

ZFP36L1 negatively regulates plasmacytoid differentiation of BCL1 cells by targeting BLIMP1 mRNA
Nasir, A., Norton, J.D., Baou, M., Zekavati, A., Bijlmakers, M.J., Thompson, S. and Murphy, J.J. 2012. ZFP36L1 negatively regulates plasmacytoid differentiation of BCL1 cells by targeting BLIMP1 mRNA. PLoS ONE. 7 (12), p. e52187. doi:10.1371/journal.pone.0052187

AU-rich RNA binding proteins in hematopoiesis and leukemogenesis
Baou, M., Norton, J.D. and Murphy, J.J. 2011. AU-rich RNA binding proteins in hematopoiesis and leukemogenesis. Blood. 118 (22), pp. 5732-5740. doi:10.1182/blood-2011-07-347237

Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells
Baou, M., Jewell, A.P., Muthurania, A., Wickremasinghe, R.G., Yong, K.L., Carr, R., Marsh, P. and Murphy, J.J. 2009. Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells. Leukemia. 23 (5), pp. 986-989. doi:10.1038/leu.2008.340

Post-transcriptional regulator protein ZFP36L1 targeting of Bcl-2 mRNA
Zekavati, A., Marsh, P. and Murphy, J.J. 2009. Post-transcriptional regulator protein ZFP36L1 targeting of Bcl-2 mRNA. 2nd European Congress of Immunology. Berlin, Germany 13 – 16 September 2009

Evidence for involvement of ZFP36L1 protein downregulation in differentiation of the murine BCL1 leukaemia cell line
Nasir, A., Roberts, H., Thompson, S. and Murphy, J.J. 2009. Evidence for involvement of ZFP36L1 protein downregulation in differentiation of the murine BCL1 leukaemia cell line. 2nd European Congress of Immunology. Berlin, Germany 13 – 16 September 2009

TIS11 family proteins and their roles in post-transcriptional gene regulation
Baou, M., Jewell, A.P. and Murphy, J.J. 2009. TIS11 family proteins and their roles in post-transcriptional gene regulation. Journal of Biomedicine and Biotechnology. doi:10.1155/2009/634520

Evidence for involvement of ZFP36L1 protein downregulation in differentiation of the murine BCL1 leukaemia cell line
Nasir, A., Roberts, H., Thompson, S. and Murphy, J.J. 2008. Evidence for involvement of ZFP36L1 protein downregulation in differentiation of the murine BCL1 leukaemia cell line. BSI Immunology Congress. Glasgow 17-21 November 2008

Mode of action of Rituximab in chronic lymphocytic leukaemia: activation of Tis11b, an inducer of mRNA instability and induction of apoptosis
Baou, M., Jewell, A.P., Yong, K.L. and Murphy, J.J. 2008. Mode of action of Rituximab in chronic lymphocytic leukaemia: activation of Tis11b, an inducer of mRNA instability and induction of apoptosis. in: Moreau, I.B. (ed.) Chronic lymphocytic leukemia: new research Nova Science Publishers. pp. 141-155

Permalink - https://westminsterresearch.westminster.ac.uk/item/9v315/stat5-in-cancer-and-immunity


Share this
Tweet
Email